BCD-261

BCD-261 is an investigational monoclonal antibody developed by Biocad for the treatment of inflammatory bowel diseases, specifically Crohn's disease and ulcerative colitis. Its mechanism of action is as a TL1A (VEGI) inhibitor, representing a novel therapeutic approach in this area. The drug is administered subcutaneously and is currently undergoing Phase 1 clinical trials to assess its safety, tolerability, pharmacodynamics, pharmacokinetics, and immunogenicity in healthy adult male volunteers. No FDA designation or approvals have been granted as of now[1][2][3][4][5].

Other names

anti-TL1A monoclonal antibodyanti-TL-1A monoclonal antibodyanti-TL 1A monoclonal antibodyanti-TL1A mAbanti-TL-1A mAbanti-TL 1A mAb